{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:37:07Z","timestamp":1788518227049,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T00:00:00Z","timestamp":1682208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T00:00:00Z","timestamp":1682208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013412","name":"Sanofi Espa\u00f1a","doi-asserted-by":"publisher","award":["Sanofi Espa\u00f1a"],"award-info":[{"award-number":["Sanofi Espa\u00f1a"]}],"id":[{"id":"10.13039\/501100013412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Scientific evidence on patients with multimorbid type 2 asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) from a united airways disease (UAD) perspective remains scarce, despite the frequent coexistence of these entities. We aimed to generate expert consensus-based recommendations for the management of UAD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using a two-round Delphi method, Spanish expert allergists, pulmonologists and otolaryngologists expressed their agreement on 32 statements (52 items) on a 9-point Likert scale, classified as appropriate (median 7\u20139), uncertain (4\u20136) or inappropriate (1\u20133). Consensus was considered when at least two-thirds of the panel scored within the range containing the median.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A panel of 30 experts reached consensus on the appropriateness of 43 out of the 52 (82.7%) items. The usefulness of certain biomarkers (tissue and peripheral blood eosinophil count, serum total IgE, and fraction of exhaled nitric oxide [FeNO]) in the identification and follow-up of type 2 inflammation, and assessment of the response to biologics, were agreed. Some of these biomarkers were also associated with disease severity and\/or recurrence after endoscopic sinus surgery (ESS). Consensus was achieved on treatment strategies related to the prescription of anti-IL-4\/IL-13 or anti-IgE agents, concomitant treatment with systemic corticosteroids, and combining or switching to biologics with a different mechanism of action, considering a number of UAD clinical scenarios.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We provide expert-based recommendations to assist in clinical decision-making for the management of patients with multimorbid type 2 asthma and CRSwNP. Specific clinical trials and real-world studies focusing on the single-entity UAD are required to address controversial items.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13223-023-00780-9","type":"journal-article","created":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T12:01:51Z","timestamp":1682251311000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Consensus on the management of united airways disease with type 2 inflammation: a multidisciplinary Delphi study"],"prefix":"10.1186","volume":"19","author":[{"given":"Marina","family":"Blanco-Aparicio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Dom\u00ednguez-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Cisneros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Col\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Casas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"del Cuvillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isam","family":"Alobid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Quirce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3463-5007","authenticated-orcid":false,"given":"Joaquim","family":"Mullol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,23]]},"reference":[{"key":"780_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/medsci7020027","author":"A Kanda","year":"2019","unstructured":"Kanda A, Kobayashi Y, Asako M, Tomoda K, Kawauchi H, Iwai H. Regulation of interaction between the upper and lower airways in united airway disease. Med Sci (Basel). 2019. https:\/\/doi.org\/10.3390\/medsci7020027.","journal-title":"Med Sci (Basel)"},{"key":"780_CR2","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1111\/all.13496","volume":"73","author":"ACA Yii","year":"2018","unstructured":"Yii ACA, Tay T-R, Choo XN, Koh MSY, Tee AKH, Wang D-Y. Precision medicine in united airways disease: a \u201ctreatable traits\u201d approach. Allergy. 2018;73:1964\u201378. https:\/\/doi.org\/10.1111\/all.13496.","journal-title":"Allergy"},{"key":"780_CR3","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.jaip.2019.02.030","volume":"7","author":"M Humbert","year":"2019","unstructured":"Humbert M, Bousquet J, Bachert C, Palomares O, Pfister P, Kottakis I, et al. IgE-mediated multimorbidities in allergic asthma and the potential for omalizumab therapy. J Allergy Clin Immunol Pract. 2019;7:1418\u201329. https:\/\/doi.org\/10.1016\/j.jaip.2019.02.030.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"780_CR4","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","volume":"9","author":"TM Laidlaw","year":"2021","unstructured":"Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP. Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunol Pract. 2021;9:1133\u201341. https:\/\/doi.org\/10.1016\/j.jaip.2020.09.063.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"780_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2500\/ajra.2011.25.3613","volume":"25","author":"DC Lin","year":"2011","unstructured":"Lin DC, Chandra RK, Tan BK, Zirkle W, Conley DB, Grammer LC, et al. Association between severity of asthma and degree of chronic rhinosinusitis. Am J Rhinol Allergy. 2011;25:205\u20138. https:\/\/doi.org\/10.2500\/ajra.2011.25.3613.","journal-title":"Am J Rhinol Allergy"},{"key":"780_CR6","doi-asserted-by":"publisher","first-page":"e12001","DOI":"10.1002\/clt2.12001","volume":"11","author":"MJ Rial","year":"2021","unstructured":"Rial MJ, \u00c1lvarez-Puebla MJ, Arismendi E, Caballero ML, Ca\u00f1as JA, Cruz MJ, et al. Clinical and inflammatory characteristics of patients with asthma in the spanish MEGA project cohort. Clin Transl Allergy. 2021;11:e12001. https:\/\/doi.org\/10.1002\/clt2.12001.","journal-title":"Clin Transl Allergy"},{"key":"780_CR7","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1111\/all.13875","volume":"74","author":"WJ Fokkens","year":"2019","unstructured":"Fokkens WJ, Lund V, Bachert C, Mullol J, Bjermer L, Bousquet J, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74:2312\u201319. https:\/\/doi.org\/10.1111\/all.13875.","journal-title":"Allergy"},{"key":"780_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.rmed.2019.03.006","volume":"151","author":"L P\u00e9rez de Llano","year":"2019","unstructured":"P\u00e9rez de Llano L, Mart\u00ednez-Morag\u00f3n E, Plaza Moral V, Trisan Alonso A, S\u00e1nchez CA, Callejas FJ, et al. Unmet therapeutic goals and potential treatable traits in a population of patients with severe uncontrolled asthma in Spain. ENEAS study. Respir Med. 2019;151:49\u201354. https:\/\/doi.org\/10.1016\/j.rmed.2019.03.006.","journal-title":"Respir Med"},{"key":"780_CR9","first-page":"24","volume":"3","author":"Z Diamant","year":"2018","unstructured":"Diamant Z, Sven-Erik Dahl\u00e9n SE, Walter Canonica G. Type 2 inflammation and the evolving profile of uncontrolled persistent asthma. Eur Med J. 2018;3:24\u201333.","journal-title":"Eur Med J"},{"key":"780_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/medicina55040095","author":"S Ahern","year":"2019","unstructured":"Ahern S. Inflammation and endotyping in chronic Rhinosinusitis-A paradigm shift. Med (Kaunas). 2019. https:\/\/doi.org\/10.3390\/medicina55040095.","journal-title":"Med (Kaunas)"},{"issue":"Suppl 2","key":"780_CR11","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1513\/AnnalsATS.201506-377AW","volume":"12","author":"EM Dunican","year":"2015","unstructured":"Dunican EM, Fahy JV. The role of type 2 inflammation in the pathogenesis of asthma exacerbations. Ann Am Thorac Soc. 2015;12(Suppl 2):144-S49. https:\/\/doi.org\/10.1513\/AnnalsATS.201506-377AW.","journal-title":"Ann Am Thorac Soc"},{"key":"780_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.600","volume":"58","author":"WJ Fokkens","year":"2020","unstructured":"Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European position paper on Rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58:1\u2013464. https:\/\/doi.org\/10.4193\/Rhin20.600.","journal-title":"Rhinology"},{"key":"780_CR13","unstructured":"GINA. Guide for health professionals: asthma management and prevention for adults and children older than 5 years. Global Initiative for Asthma; 2021."},{"key":"780_CR14","doi-asserted-by":"publisher","first-page":"873","DOI":"10.2147\/jaa.s258438","volume":"14","author":"CJ Morse","year":"2021","unstructured":"Morse CJ, Miller C, Senior B. Management of chronic rhinosinusitis with nasal polyposis in the era of biologics. J Asthma Allergy. 2021;14:873\u201382. https:\/\/doi.org\/10.2147\/jaa.s258438.","journal-title":"J Asthma Allergy"},{"key":"780_CR15","doi-asserted-by":"publisher","first-page":"e12049","DOI":"10.1002\/clt2.12049","volume":"11","author":"C M\u00fcmmler","year":"2021","unstructured":"M\u00fcmmler C, D\u00fcnzelmann K, Kneidinger N, Barnikel M, Munker D, Gr\u00f6ger M, et al. Real-life effectiveness of biological therapies on symptoms in severe asthma with comorbid CRSwNP. Clin Transl Allergy. 2021;11:e12049. https:\/\/doi.org\/10.1002\/clt2.12049.","journal-title":"Clin Transl Allergy"},{"key":"780_CR16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.arbres.2019.12.029","volume":"56","author":"V Plaza","year":"2020","unstructured":"Plaza V, del Cuvillo A, Soto-Retes L, Gras JR, Cisneros C, S\u00e1nchez-Cuellar S, et al. Functional endoscopic sinus surgery for nasal polyposis in Asthma Patients: impact on bronchial inflammation. Arch Bronconeumol (Engl Ed). 2020;56:403\u201305. https:\/\/doi.org\/10.1016\/j.arbres.2019.12.029.","journal-title":"Arch Bronconeumol (Engl Ed)"},{"key":"780_CR17","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1080\/02770903.2020.1729380","volume":"58","author":"K Hamada","year":"2021","unstructured":"Hamada K, Oishi K, Chikumoto A, Murakawa K, Ohteru Y, Matsuda K, et al. Impact of sinus surgery on type 2 airway and systemic inflammation in asthma. J Asthma. 2021;58:750\u201358. https:\/\/doi.org\/10.1080\/02770903.2020.1729380.","journal-title":"J Asthma"},{"key":"780_CR18","doi-asserted-by":"publisher","DOI":"10.1177\/01455613211032006","author":"T Terada","year":"2021","unstructured":"Terada T, Inui T, Moriyama K, Noro K, Kikuoka Y, Omura S, et al. Effects of endoscopic sinus surgery for eosinophilic chronic rhinosinusitis on respiratory functions and FeNO production in the lower respiratory tract. Ear Nose Throat J. 2021. https:\/\/doi.org\/10.1177\/01455613211032006.","journal-title":"Ear Nose Throat J"},{"key":"780_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.arbres.2021.05.010","author":"V Plaza","year":"2021","unstructured":"Plaza V, Alobid I, Alvarez C, Blanco M, Ferreira J, Garc\u00eda G, et al. Spanish asthma management guidelines (GEMA) VERSION 5.1. highlights and controversies. Arch Bronconeumol (Engl Ed). 2021. https:\/\/doi.org\/10.1016\/j.arbres.2021.05.010.","journal-title":"Arch Bronconeumol (Engl Ed)"},{"key":"780_CR20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/all.14611","volume":"76","author":"A Bourdin","year":"2021","unstructured":"Bourdin A, Papi AA, Corren J, Virchow JC, Rice MS, Deniz Y, et al. Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline. Allergy. 2021;76:269\u201380. https:\/\/doi.org\/10.1111\/all.14611.","journal-title":"Allergy"},{"key":"780_CR21","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/j.jaip.2020.03.038","volume":"8","author":"R Buhl","year":"2020","unstructured":"Buhl R, Korn S, Menzies-Gow A, Aubier M, Chapman KR, Canonica GW, et al. Prospective, single-arm, longitudinal study of biomarkers in real-world patients with severe asthma. J Allergy Clin Immunol Pract. 2020;8:2630-39e6. https:\/\/doi.org\/10.1016\/j.jaip.2020.03.038.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"780_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2147\/jaa.s288260","volume":"14","author":"C Emson","year":"2021","unstructured":"Emson C, Corren J, Salapa K, Hellqvist A, Parnes JR, Colice G. Efficacy of tezepelumab in patients with severe, uncontrolled asthma with and without nasal polyposis: a post hoc analysis of the phase 2b PATHWAY study. J Asthma Allergy. 2021;14:91\u20139. https:\/\/doi.org\/10.2147\/jaa.s288260.","journal-title":"J Asthma Allergy"},{"key":"780_CR23","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/s0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394:1638\u201350. https:\/\/doi.org\/10.1016\/s0140-6736(19)31881-1.","journal-title":"Lancet"},{"key":"780_CR24","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","volume":"9","author":"JK Han","year":"2021","unstructured":"Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9:1141\u201353. https:\/\/doi.org\/10.1016\/S2213-2600(21)00097-7.","journal-title":"Lancet Respir Med"},{"key":"780_CR25","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","volume":"146","author":"P Gevaert","year":"2020","unstructured":"Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146:595\u2013605. https:\/\/doi.org\/10.1016\/j.jaci.2020.05.032.","journal-title":"J Allergy Clin Immunol"},{"key":"780_CR26","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0085-2019","author":"A Bourdin","year":"2020","unstructured":"Bourdin A, Adcock I, Berger P, Bonniaud P, Chanson P, Chenivesse C, et al. How can we minimise the use of regular oral corticosteroids in asthma? Eur Respir Rev. 2020. https:\/\/doi.org\/10.1183\/16000617.0085-2019.","journal-title":"Eur Respir Rev"},{"key":"780_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9070787","author":"Y Kobayashi","year":"2021","unstructured":"Kobayashi Y, Kanda A, Bui DV, Yun Y, Nguyen LM, Chu HH, et al. Omalizumab restores response to corticosteroids in patients with eosinophilic chronic rhinosinusitis and severe asthma. Biomedicines. 2021. https:\/\/doi.org\/10.3390\/biomedicines9070787.","journal-title":"Biomedicines"},{"key":"780_CR28","doi-asserted-by":"publisher","first-page":"301","DOI":"10.4193\/Rhin20.415","volume":"59","author":"M Desrosiers","year":"2021","unstructured":"Desrosiers M, Mannent LP, Amin N, Canonica GW, Hellings PW, Gevaert P, et al. Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP. Rhinology. 2021;59:301\u201311. https:\/\/doi.org\/10.4193\/Rhin20.415.","journal-title":"Rhinology"},{"key":"780_CR29","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","volume":"67","author":"IR Diamond","year":"2014","unstructured":"Diamond IR, Grant RC, Feldman BM, Pencharz PB, Ling SC, Moore AM, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of delphi studies. J Clin Epidemiol. 2014;67:401\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2013.12.002.","journal-title":"J Clin Epidemiol"},{"key":"780_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.04.039","author":"J Mullol","year":"2022","unstructured":"Mullol J, Maldonado M, Castillo JA, Miguel-Blanco C, D\u00e1vila I, Dom\u00ednguez-Ortega J, et al. Management of united airway disease focused on patients with asthma and chronic rhinosinusitis with nasal polyps: a systematic review. J Allergy Clin Immunol Pract. 2022. https:\/\/doi.org\/10.1016\/j.jaip.2022.04.039.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"780_CR31","unstructured":"Fitch K, Bernstein Sj AM, Col. The rand\/UCLA appropriateness method user\u2019s manual. library of congress cataloging-in-publication Data.\u00a02001."},{"key":"780_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s10459-010-9222-y","author":"G Norman","year":"2010","unstructured":"Norman G. Likert scales, levels of measurement and the \u201claws\u201d of statistics. Adv Health Sci Educ. 2010. https:\/\/doi.org\/10.1007\/s10459-010-9222-y.","journal-title":"Adv Health Sci Educ"},{"key":"780_CR33","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2147\/jaa.s321212","volume":"14","author":"D Price","year":"2021","unstructured":"Price D, Menzies-Gow A, Bachert C, Canonica GW, Kocks J, Khan AH, et al. Association between a type 2 inflammatory disease burden score and outcomes among patients with asthma. J Asthma Allergy. 2021;14:1173\u201383. https:\/\/doi.org\/10.2147\/jaa.s321212.","journal-title":"J Asthma Allergy"},{"key":"780_CR34","doi-asserted-by":"publisher","first-page":"101332","DOI":"10.1016\/j.smim.2019.101332","volume":"46","author":"D Narendra","year":"2019","unstructured":"Narendra D, Blixt J, Hanania NA. Immunological biomarkers in severe asthma. Semin Immunol. 2019;46:101332. https:\/\/doi.org\/10.1016\/j.smim.2019.101332.","journal-title":"Semin Immunol"},{"key":"780_CR35","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.anai.2020.03.004","volume":"125","author":"FLM Ricciardolo","year":"2020","unstructured":"Ricciardolo FLM, Levra S, Sprio AE, Bertolini F, Carriero V, Gallo F, et al. A real-world assessment of asthma with chronic rhinosinusitis. Ann Allergy Asthma Immunol. 2020;125:65\u201371. https:\/\/doi.org\/10.1016\/j.anai.2020.03.004.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"780_CR36","doi-asserted-by":"publisher","DOI":"10.14639\/0392-100x-n1614","author":"E De Corso","year":"2021","unstructured":"De Corso E, Bellocchi G, De Benedetto M, Lombardo N, Macchi A, Malvezzi L, et al. Biologics for severe uncontrolled chronic rhinosinusitis with nasal polyps: a change management approach. consensus of the joint committee of Italian society of otorhinolaryngology on biologics in rhinology. Acta Otorhinolaryngol Ital. 2021. https:\/\/doi.org\/10.14639\/0392-100x-n1614.","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"780_CR37","first-page":"120","volume":"25","author":"I Davila","year":"2015","unstructured":"Davila I, Valero A, Entrenas LM, Valveny N. Relationship between serum total IgE and disease severity in patients with allergic asthma in Spain. J Investig Allergol Clin Immunol. 2015;25:120\u20137.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"780_CR38","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S2213-2600(21)00170-3","volume":"9","author":"KF Chung","year":"2021","unstructured":"Chung KF. Increasing utility of FeNO as a biomarker of type-2 inflammation in severe asthma. Lancet Respir Med. 2021;9:1083\u201384. https:\/\/doi.org\/10.1016\/S2213-2600(21)00170-3.","journal-title":"Lancet Respir Med"},{"key":"780_CR39","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01633-2019","author":"A Menzies-Gow","year":"2020","unstructured":"Menzies-Gow A, Mansur AH, Brightling CE. Clinical utility of fractional exhaled nitric oxide (FeNO) in severe asthma management. Eur Respir J. 2020. https:\/\/doi.org\/10.1183\/13993003.01633-2019.","journal-title":"Eur Respir J"},{"key":"780_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2021.06.007","author":"R Chan","year":"2021","unstructured":"Chan R, Lipworth B. Impact of nasal polyps on endotype and phenotype in patients with moderate to severe asthma. Ann Allergy Asthma Immunol. 2021. https:\/\/doi.org\/10.1016\/j.anai.2021.06.007. 127:548 \u2013 52.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"780_CR41","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12931-018-0813-0","volume":"19","author":"A Matucci","year":"2018","unstructured":"Matucci A, Vultaggio A, Maggi E, Kasujee I. Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question? Respir Res. 2018;19:113. https:\/\/doi.org\/10.1186\/s12931-018-0813-0.","journal-title":"Respir Res"},{"key":"780_CR42","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/00016489.2020.1844288","volume":"141","author":"X Wang","year":"2021","unstructured":"Wang X, Meng Y, Lou H, Wang K, Wang C, Zhang L. Blood eosinophil count combined with asthma history could predict chronic rhinosinusitis with nasal polyp recurrence. Acta Otolaryngol. 2021;141:279\u201385. https:\/\/doi.org\/10.1080\/00016489.2020.1844288.","journal-title":"Acta Otolaryngol"},{"key":"780_CR43","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/alr.22194","volume":"8","author":"T McHugh","year":"2018","unstructured":"McHugh T, Snidvongs K, Xie M, Banglawala S, Sommer D. High tissue eosinophilia as a marker to predict recurrence for eosinophilic chronic rhinosinusitis: a systematic review and meta-analysis. Int Forum Allergy Rhinol. 2018;8:1421\u201329. https:\/\/doi.org\/10.1002\/alr.22194.","journal-title":"Int Forum Allergy Rhinol"},{"key":"780_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.08.030","author":"C Bachert","year":"2021","unstructured":"Bachert C, Han JK, Desrosiers MY, Gevaert P, Heffler E, Hopkins C, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2021. https:\/\/doi.org\/10.1016\/j.jaci.2021.08.030.","journal-title":"J Allergy Clin Immunol"},{"key":"780_CR45","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","volume":"140","author":"C Bachert","year":"2017","unstructured":"Bachert C, Sousa AR, Lund VJ, Scadding GK, Gevaert P, Nasser S, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol. 2017;140:1024\u201331e14. https:\/\/doi.org\/10.1016\/j.jaci.2017.05.044.","journal-title":"J Allergy Clin Immunol"},{"key":"780_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.06.013","author":"G Ortega","year":"2019","unstructured":"Ortega G, Tongchinsub P, Carr T. Combination biologic therapy for severe persistent asthma. Ann Allergy Asthma Immunol. 2019. https:\/\/doi.org\/10.1016\/j.anai.2019.06.013. 123:309 \u2013 11.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"780_CR47","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/cea.13809","volume":"51","author":"AI Papaioannou","year":"2021","unstructured":"Papaioannou AI, Fouka E, Papakosta D, Papiris S, Loukides S. Switching between biologics in severe asthma patients. when the first choice is not proven to be the best. Clin Exp Allergy. 2021;51:221\u20137. https:\/\/doi.org\/10.1111\/cea.13809.","journal-title":"Clin Exp Allergy"},{"key":"780_CR48","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1016\/j.jaip.2021.05.044","volume":"9","author":"G Spadaro","year":"2021","unstructured":"Spadaro G, Lagnese G, Punziano A, Poto R, Varricchi G, Detoraki A. The immunology of switching biologics in severe eosinophilic asthma patients. J Allergy Clin Immunol Pract. 2021;9:3528\u201329. https:\/\/doi.org\/10.1016\/j.jaip.2021.05.044.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"780_CR49","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2147\/jaa.s311975","volume":"14","author":"T Numata","year":"2021","unstructured":"Numata T, Araya J, Miyagawa H, Okuda K, Fujita Y, Utsumi H, et al. Effectiveness of switching biologics for severe asthma patients in Japan: a single-center retrospective study. J Asthma Allergy. 2021;14:609\u201318. https:\/\/doi.org\/10.2147\/jaa.s311975.","journal-title":"J Asthma Allergy"},{"key":"780_CR50","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","volume":"147","author":"C Bachert","year":"2021","unstructured":"Bachert C, Han JK, Wagenmann M, Hosemann W, Lee SE, Backer V, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management. J Allergy Clin Immunol. 2021;147:29\u201336. https:\/\/doi.org\/10.1016\/j.jaci.2020.11.013.","journal-title":"J Allergy Clin Immunol"},{"key":"780_CR51","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/alr.21182","volume":"3","author":"R Vashishta","year":"2013","unstructured":"Vashishta R, Soler ZM, Nguyen SA, Schlosser RJ. A systematic review and meta-analysis of asthma outcomes following endoscopic sinus surgery for chronic rhinosinusitis. Int Forum Allergy Rhinol. 2013;3:788\u201394. https:\/\/doi.org\/10.1002\/alr.21182.","journal-title":"Int Forum Allergy Rhinol"},{"key":"780_CR52","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/lary.27764","volume":"129","author":"BR Haxel","year":"2019","unstructured":"Haxel BR. Recovery of olfaction after sinus surgery for chronic rhinosinusitis: a review. Laryngoscope. 2019;129:1053\u201359. https:\/\/doi.org\/10.1002\/lary.27764.","journal-title":"Laryngoscope"},{"key":"780_CR53","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.jaci.2020.01.024","volume":"145","author":"J Mullol","year":"2020","unstructured":"Mullol J, Mari\u00f1o-S\u00e1nchez F, Valls M, Alobid I, Marin C. The sense of smell in chronic rhinosinusitis. J Allergy Clin Immunol. 2020;145:773\u201376. https:\/\/doi.org\/10.1016\/j.jaci.2020.01.024.","journal-title":"J Allergy Clin Immunol"}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-023-00780-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-023-00780-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-023-00780-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T12:01:57Z","timestamp":1682251317000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacijournal.biomedcentral.com\/articles\/10.1186\/s13223-023-00780-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,23]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["780"],"URL":"https:\/\/doi.org\/10.1186\/s13223-023-00780-9","relation":{},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,23]]},"assertion":[{"value":"8 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MBA has received honoraria for lectures, courses, participation in monographs and standards, or scientific advice from AstraZeneca, Sanofi, Esteve, GSK, Menarini, Novartis, Chiesi, and TEVA. JDO has received funding for research and\/or honoraria for consultancy and conferences from AstraZeneca, Chiesi, GSK, Bial, Novartis, Sanofi, and TEVA; and speaker fees from ALK, LETI Pharma, and Mundipharma. CCis has received financial aid from AstraZeneca, Chiesi, Novartis, Mundipharma, GSK, Pfizer, Menarini, and Sanofi for advisory services, papers, research studies, attendance at congresses or training courses. CCol has received honoraria for lectures, courses, participation in monographs and standards or scientific advice from AstraZeneca, Sanofi, GSK, Novartis, Viatris and Chiesi. FCM has received honoraria for lectures, courses, participation in monographs and standards or scientific advice from AstraZeneca, Chiesi, GSK, Novartis, Sanofi, and TEVA. AC reports grants and personal fees from MYLAN, FAES Pharma, Novartis, Allakos, and Sanofi; personal fees from ALK, GSK, MSD, AstraZeneca, and TEVA, outside the submitted work. IA has received honoraria for consultancy and conferences from Viatris, Sanofi, GSK, MSD, Menarini, GAES, Aural, and Novartis. SQ has received honoraria for consultancy and conferences from AstraZeneca, GSK and Sanofi, and speaker fees from Chiesi, Mundipharma, Novartis, and TEVA. JM is a member of national or international advisory boards and has received speaker fees or funding for clinical trials and research projects from Allakos, AstraZeneca, GSK, Menarini, Mitsubishi-Tanabe, MSD, Mylan-MEDA Pharma (Viatris), Novartis, Regeneron Pharmaceuticals, Sanofi, UCB Pharma, and Uriach Group.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}